Naber D - Search Results

1

Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study.

Filts Y, Litman RE, Martínez J, Anta L, Naber D, Correll CU. Filts Y, et al. Among authors: naber d. Schizophr Res. 2022 Jan;239:83-91. doi: 10.1016/j.schres.2021.11.030. Epub 2021 Nov 27. Schizophr Res. 2022. PMID: 34847501 Free article. Clinical Trial.

2

Corrigendum to "Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study" [Schizophr. Res. 239 (2022) 83-91].

Filts Y, Litman RE, Martínez J, Anta L, Naber D, Correll CU. Filts Y, et al. Among authors: naber d. Schizophr Res. 2022 Aug;246:258-259. doi: 10.1016/j.schres.2022.06.037. Epub 2022 Jul 16. Schizophr Res. 2022. PMID: 35853294 No abstract available.

3

Efficacy and safety of once-monthly Risperidone ISM^® in schizophrenic patients with an acute exacerbation.

Correll CU, Litman RE, Filts Y, Llaudó J, Naber D, Torres F, Martínez J. Correll CU, et al. Among authors: naber d. NPJ Schizophr. 2020 Nov 25;6(1):37. doi: 10.1038/s41537-020-00127-y. NPJ Schizophr. 2020. PMID: 33239746 Free PMC article.

4

Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study.

Naber D, Baker RA, Eramo A, Forray C, Hansen K, Sapin C, Peters-Strickland T, Nylander AG, Hertel P, Nitschky Schmidt S, Loze JY, Potkin SG. Naber D, et al. Schizophr Res. 2018 Feb;192:205-210. doi: 10.1016/j.schres.2017.04.013. Epub 2017 Apr 19. Schizophr Res. 2018. PMID: 28433498 Free article.

5

Validation of a Clinical Global Impression Scale for Aggression (CGI-A) in a sample of 558 psychiatric patients.

Huber CG, Lambert M, Naber D, Schacht A, Hundemer HP, Wagner TT, Schimmelmann BG. Huber CG, et al. Among authors: naber d. Schizophr Res. 2008 Mar;100(1-3):342-8. doi: 10.1016/j.schres.2007.12.480. Epub 2008 Feb 5. Schizophr Res. 2008. PMID: 18255271

6

Long-term patterns of subjective wellbeing in schizophrenia: cluster, predictors of cluster affiliation, and their relation to recovery criteria in 2842 patients followed over 3 years.

Lambert M, Schimmelmann BG, Schacht A, Karow A, Wagner T, Wehmeier PM, Huber CG, Hundemer HP, Dittmann RW, Naber D. Lambert M, et al. Among authors: naber d. Schizophr Res. 2009 Feb;107(2-3):165-72. doi: 10.1016/j.schres.2008.08.035. Epub 2008 Oct 8. Schizophr Res. 2009. PMID: 18842393

7

Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.

Naber D, Hansen K, Forray C, Baker RA, Sapin C, Beillat M, Peters-Strickland T, Nylander AG, Hertel P, Andersen HS, Eramo A, Loze JY, Potkin SG. Naber D, et al. Schizophr Res. 2015 Oct;168(1-2):498-504. doi: 10.1016/j.schres.2015.07.007. Epub 2015 Jul 29. Schizophr Res. 2015. PMID: 26232241 Free article. Clinical Trial.

8

Early detection and integrated care for adolescents and young adults with severe psychotic disorders: rationales and design of the Integrated Care in Early Psychosis Study (ACCESS III).

Lambert M, Schöttle D, Sengutta M, Ruppelt F, Rohenkohl A, Luedecke D, Nawara LA, Galling B, Falk AL, Wittmann L, Niehaus V, Sarikaya G, Handwerk U, Rothländer W, Rietschel L, Gagern C, Lange B, Meigel-Schleiff C, Naber D, Schulte-Markwort M, Krüger H, Unger HP, Sippel S, Ott S, Romer G, Daubmann A, Wegscheider K, Correll CU, Schimmelmann BG, Bock T, Gallinat J, Karow A. Lambert M, et al. Among authors: naber d. Early Interv Psychiatry. 2018 Feb;12(1):96-106. doi: 10.1111/eip.12361. Epub 2016 Sep 12. Early Interv Psychiatry. 2018. PMID: 27618789

9

Subjective wellbeing under quetiapine treatment: effect of diagnosis, mood state, and anxiety.

Lambert M, Naber D, Karow A, Huber CG, Köhler J, Heymann J, Schimmelmann BG. Lambert M, et al. Among authors: naber d. Schizophr Res. 2009 May;110(1-3):72-9. doi: 10.1016/j.schres.2009.03.004. Epub 2009 Mar 24. Schizophr Res. 2009. PMID: 19321310 Clinical Trial.

10

Subjective well-being in schizophrenia: a randomised controlled open-label 12-month non-inferiority study comparing quetiapine XR with risperidone (RECOVER).

Naber D, Peuskens J, Schwarzmann N, Goltz M, Krüger H, Lambert M, Haro JM. Naber D, et al. Eur Neuropsychopharmacol. 2013 Oct;23(10):1257-69. doi: 10.1016/j.euroneuro.2013.07.006. Epub 2013 Jul 29. Eur Neuropsychopharmacol. 2013. PMID: 23953270 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

341 results

Search Page

Filters